RA
TVTX icon

Royce & Associates’s Travere Therapeutics TVTX Stock Holding History

Royce & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123,250
Closed -$2.95M – 814
2025
Q3 		$2.95M Sell
123,250
-257,747
-68% -$4.85M 0.03% 549
2025
Q2 		$5.64M Buy
+380,997
New +$6.32M 0.06% 433
2024
Q3 		– Sell
-47,573
Closed -$391K – 909
2024
Q2 		$391K Hold
47,573
– – ﹤0.01% 806
2024
Q1 		$367K Buy
47,573
+5,932
+14% +$50K ﹤0.01% 809
2023
Q4 		$374K Buy
41,641
+23,302
+127% +$170K ﹤0.01% 808
2023
Q3 		$164K Buy
+18,339
New +$259K ﹤0.01% 884

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return